Firehawk

The revolutionary third-generation drug-eluting stent ("DES") Firehawk is the result of eight years of research and development of MicroPort and it is the world's first and only target eluting stent. As the world's lowest drug dosage stent, Firehawk combines the merits of the bare metal stent and DES. It adopts unique in-groove abluminal coating design and target-eluting technique, which allows Firehawk to achieve the same clinical efficacy with significantly low drug loading, benefiting vascular early healing. The TARGET AC trial is a prospective, multi-center, randomized controlled clinical trial consisting of entirely European based patients. This clinical study enrolled its first patient in December 2015 and completed enrollment of its last patient in October 2016. In total, there were 1,654 patients enrolled from 21 clinical study sites throughout Europe. In addition, the trial design included an OCT (Optical Coherence Tomography) sub-study consisting of 50 patients at three months post implantation and a QCA (Quantitative Coronary Angiography) sub-study consisting of 176 patients at 13 months. As the first Chinese medical device company launched a large-scale post-market clinical trial in Europe, MicroPort is extremely careful in carrying out the TARGET global clinical programs. Up to date, over 2,900 patients were enrolled in TARGET series clinical programs. The increasingly more clinical data have further proved Firehawk's safety and efficacy.